Allergan, Inc Patent Portfolio Statistics

Allergan, Inc

Allergan, Inc`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Allergan, Inc look like?

Total Applications:	3
Granted Patents:	2
Grant Index	66.67 %
Abandoned/Rejected Applications:	1 (33.33%)
In-Process Applications:	0
Average Grant Time:	2.96 Years
Average Office Actions:	1.5

Which Technology Area Allergan, Inc is filing most patents in? (Last 10 years)

Art Unit	Definition	Total Applications
1614	–	1
1618	Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs	1
1625	Organic Chemistry	1

How many patents are Allergan, Inc filing every year?

Year	Total Applications
2022	0*
2021	0*
2020	0
2019	0
2018	0

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Allergan, Inc in USPTO?

Publication number: US20210393749A1

Abstract:
Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (NDO) and for reducing need for or frequency of clean intermittent catherization (CIC) by injecting a clostridial derivative to the bladder of a patient are disclosed.

Publication date: 2021-12-23
Applicant: Allergan, Inc
Inventors: C Cornelia Haag-Molkenteller

Publication number: –

Abstract:
None

Publication date: –
Applicant: Allergan, Inc
Inventors: Gregory Nicholson

Publication number: US20220023186A1

Abstract:
The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.

Publication date: 2022-01-27
Applicant: Allergan, Inc
Inventors: Gabriel N Njikang

How are Allergan, Inc’s applications performing in USPTO?

Application Number	Title	Status	Art Unit	Examiner
17465124	Botulinum Toxin Administration For Treatment Of Neurogenic Detrusor Overactivity Associated Urinary Incontinence	Docketed New Case – Ready for Examination	OPAP	Central, Docket
17429237	Combination Therapy Using Clostridial Toxin Derivative And At Least One Chemical Depolarizing Agent	Application Undergoing Preexam Processing	1653	–
17396597	Dermal Filler Compositions	–	OPAP	Central, Docket
17384388	Animal Protein-Free Pharmaceutical Compositions	Response to Non-Final Office Action Entered and Forwarded to Examiner	1645	Minnifield, Nita M
17443083	Intraocular Implant With High Loading Of A Prostamide	–	OPAP	Central, Docket